Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
Evaluation of a Mechanical Insufflation-exsufflation Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders: a Prospective, Randomized, Controlled, Multicenter Study
The hypothesis is that a mechanical insufflation-exsufflation (MI-E) is associated with a decrease in the number of intubations and more rapid clinical improvement in children and adults with neuromuscular disease who are admitted for an acute respiratory exacerbation.In this prospective, randomised, multicenter study, 55 patients will be treated with standard treatment and a MI-E, and 55 patients with standard treatment and standard respiratory physiotherapy. The primary objective is the reduction of the number of patients requiring invasive ventilatory support (endotracheal intubation or tracheotomy) in the group treated with MI-E (MI-E group). The main secondary objectives are a reduction in hospital stay and an improvement in clinical condition, dyspnea and respiratory muscle function.
Justification Respiratory muscle weakness reduces the efficacy of the cough reflex in
patients with neuromuscular disorders and exposes them to the risk of acute respiratory
failure. Mechanical insufflation-exsufflation devices assist cough and have been shown to be
efficient in increasing the cough expiratory flow in children and adults with neuromuscular
disease and decreasing the risk of intubation in a limited population of hospitalized adults
with acute respiratory failure.
Primary objective The goal is to record the efficacy of mechanical insufflation-exsufflation
(MI-E) during acute respiratory failure in patients with neuromuscular disorders.The primary
objective is the reduction of the number of patients requiring invasive ventilatory support
(endotracheal intubation or tracheotomy) in the group treated with MI-E (MI-E group)
compared to the group treated with traditional chest physiotherapy without MI-E (Control
group).
Secondary objectives
In the MI-E group, compared to the Control group:
1. Decrease in the length of hospitalization in the intensive care unit (ICU)
2. Decrease in the total length of hospitalization
3. Decrease in the incidence of bronchoscopy-assisted aspiration
4. Decrease in the duration of oxygen therapy
5. Decrease in the daily length of noninvasive positive pressure ventilation (NPPV)
6. Improvement in blood gases on room air during hospitalization
7. Improvement of the peak cough flow (PCF)
8. Improvement of the vital capacity (VC), maximal inspiratory (PImax) and expiratory
(PEmax) pressures, sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF)
and dyspnea during hospitalization.
9. Decrease in the number of secondary tracheotomies (for weaning of ventilatory support)
Type of study Prospective, randomized, controlled, multicenter study
Number of subjects The calculation of the number of subjects is based on two retrospective
studies. In the study by VIANELLO, which included 11 adults hospitalized in the ICU for
respiratory failure, the number of therapeutic failures, defined as the need for a "mini"
tracheotomy or intubation, was significantly less in the group using MI-E than in a group of
16 historical control patients [2 failures in the MI-E group (18%) versus 10 failures in the
control group (63%), p<0.05] (1). Another study reported 19 successes (80%) versus 5
failures on MI-E (2).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
| Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
| Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
| Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
| Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
| Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
| Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
| Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
| Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
| Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
| Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
| Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
| Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
| Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
| Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |